Humana Inc. Files 8-K for Regulation FD Disclosure

TL;DR

Humana filed an 8-K for a Reg FD disclosure, no major news.

AI Summary

Humana Inc. filed an 8-K on June 3, 2024, to report a Regulation FD Disclosure. The filing does not contain specific financial figures or new material events beyond the disclosure itself.

Why It Matters

This filing indicates Humana Inc. is adhering to disclosure regulations, ensuring timely and fair information dissemination to the public.

Risk Assessment

Risk Level: low — The filing is a standard regulatory disclosure and does not indicate any immediate financial or operational risks.

Key Players & Entities

• HUMANA INC (company) — Registrant
• Delaware (jurisdiction) — State of incorporation
• Louisville (location) — Principal executive offices city
• Kentucky (location) — Principal executive offices state

FAQ

From the Filing

0000049071-24-000027.txt : 20240603 0000049071-24-000027.hdr.sgml : 20240603 20240603073017 ACCESSION NUMBER: 0000049071-24-000027 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20240603 ITEM INFORMATION: Regulation FD Disclosure FILED AS OF DATE: 20240603 DATE AS OF CHANGE: 20240603 FILER: COMPANY DATA: COMPANY CONFORMED NAME: HUMANA INC CENTRAL INDEX KEY: 0000049071 STANDARD INDUSTRIAL CLASSIFICATION: HOSPITAL & MEDICAL SERVICE PLANS [6324] ORGANIZATION NAME: 02 Finance IRS NUMBER: 610647538 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-05975 FILM NUMBER: 241011989 BUSINESS ADDRESS: STREET 1: 500 W MAIN ST CITY: LOUISVILLE STATE: KY ZIP: 40202 BUSINESS PHONE: 5025801000 MAIL ADDRESS: STREET 1: 500 W. MAIN ST CITY: LOUISVILLE STATE: KY ZIP: 40202 FORMER COMPANY: FORMER CONFORMED NAME: EXTENDICARE INC DATE OF NAME CHANGE: 19740404 FORMER COMPANY: FORMER CONFORMED NAME: HERITAGE HOUSE OF AMERICA INC DATE OF NAME CHANGE: 19671129 8-K 1 hum-20240603.htm 8-K hum-20240603 0000049071 false 0000049071 2024-06-03 2024-06-03 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 3, 2024 ( June 3, 2024 ) Humana Inc. (Exact name of registrant as specified in its charter) Delaware 001-5975 61-0647538 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.) 500 West Main Street , Louisville , Kentucky 40202 (Address of principal executive offices, including zip code) ( 502 ) 580-1000 (Registrant’s telephone number, including area code) (Former name or former address, if changed since last report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol Name of each exchange on which registered Common Stock HUM New York Stock Exchange Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2). Emerging growth company   ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.   ☐ Item 7.01 Regulation FD Disclosure. Members of Humana Inc.’s (the “Company”) senior management team are scheduled to meet with investors and analysts between June 3, 2024 and June 28, 2024. During these meetings, the Company intends to reaffirm its guidance of approximately $13.93 in diluted earnings per common share (“EPS”) or approximately $16.00 in adjusted earnings per common share (“Adjusted EPS”), in each case for the year ending December 31, 2024 (“FY 2024”). This guidance is consistent with the guidance issued in Humana’s press release dated April 24, 2024. The Company has included Adjusted EPS in this current report, a financial measure that is not in accordance with Generally Accepted Accounting Principles (“G